Bayer Asundexian Trial Results Boost Shares
Bayer asundexian trial results lifted shares after Phase III met endpoints without extra major bleeding, prompting investors to reprice the pharma unit.
KEY TAKEAWAYS
- OCEANIC-STROKE Phase III cut recurrent ischemic stroke risk without increasing ISTH major bleeding.
- Shares rose 8% to 11% following the topline results as investors repriced Bayer's pharma outlook.
- Bayer will engage regulators globally and present full data at an upcoming scientific congress.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
On Nov. 23, 2025, Bayer AG (BAYRY) reported that its investigational anticoagulant asundexian significantly lowered the risk of recurrent ischemic stroke without increasing major bleeding. The positive Phase III results reversed earlier setbacks and boosted confidence in Bayer’s pharmaceutical division.
Trial Results and Design
Bayer said in a press release that the OCEANIC-STROKE trial was a Phase III, multicenter, randomized, double-blind, placebo-controlled, event-driven study. It enrolled more than 12,300 patients who recently experienced non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. All participants received antiplatelet therapy.
The trial compared asundexian 50 mg once daily plus antiplatelet therapy against placebo plus antiplatelet therapy. Bayer reported a statistically significant reduction in recurrent ischemic stroke with no increase in major bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH). This marks the first successful Phase III study in the Factor XIa inhibitor drug class.
Christian Rommel, head of research and development at Bayer Pharmaceuticals, said in the release, “We are excited by these positive topline findings which highlight the potential of Factor XIa inhibition as a new way to help protect patients from a recurrent stroke.”
Market Reaction and Outlook
Shares rose between 8% and 11% following the trial news, reflecting renewed investor confidence in Bayer’s drug pipeline. Analysts described the topline results as a material de-risking event and cited blockbuster potential, with some projecting annual sales in the billions.
The results reverse a 2023 setback when Bayer halted the OCEANIC-AF trial in atrial fibrillation after asundexian showed inferior efficacy compared with apixaban. Asundexian holds FDA Fast Track designation for stroke prevention after non-cardioembolic ischemic stroke but is not yet approved in any country.
Bayer said it will engage health authorities worldwide to prepare marketing authorization submissions. Detailed trial data will be presented at an upcoming scientific congress.
